FindTrial
Sign In

Temocillin

DRUG11 trials

Sponsors

Assistance Publique Hopitaux De Paris, Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla, Belpharma s.a., Université Catholique de Louvain, University Hospital, Grenoble

Conditions

Antibacterial AgentsBacteremiaDrug MonitoringInfectionInfections due to EnterobacteriaceaeInfections, BacterialInfectious DiseaseIntensive Care

Phase 3

Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections
CompletedNCT03543436
Assistance Publique - Hôpitaux de ParisUrinary Tract Infections
Start: 2019-01-04End: 2020-12-14Updated: 2025-11-20
Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins
CompletedNCT04478721
Fundación Pública Andaluza para la gestión de la Investigación en SevillaBacteremia
Start: 2020-12-15End: 2024-12-26Updated: 2026-01-23
COTRIVAP - Efficacy of cotrimoxazole as a de-escalation treatment of Ventilator-Associated Pneumonia in intensive care unit. Multicentric non-inferiority randomised controlled trial
CompletedCTIS2023-505108-52-00
Assistance Publique Hopitaux De ParisIntensive Care, Ventilator-associated Pneumonia
Start: 2023-12-20End: 2025-09-19Target: 628Updated: 2025-04-23
Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ):randomised, pragmatic trial
CompletedCTIS2023-508440-21-00
Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De SevillaInfections due to Enterobacteriaceae
Start: 2024-05-21End: 2024-12-26Target: 334Updated: 2024-10-01
Efficacy of Temocillin compared to standard of care in the Treatment of Neisseria gonorrhoeae Infections: A Multicenter Randomized Controlled Non-Inferiority Trial (TEMtoGo).
Not yet recruitingCTIS2025-524475-23-00
Assistance Publique Hopitaux De ParisNeisseria gonorrhoeae Infections
Target: 360Updated: 2026-05-18

Phase 4

Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL)/AmpC Enterobacteriaceae
WithdrawnNCT01543347
Belpharma s.a.Urinary Tract Infection
Start: 2012-02-29End: 2012-11-30Updated: 2013-01-29
Temocillin Pharmacokinetics in Paediatrics
NCT02260102
Université Catholique de LouvainInfection, Liver Dysfunction, Urinary Tract Infection
Start: 2016-02-17End: 2022-12-31Target: 45Updated: 2022-05-31
Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae
NCT02681263
University Hospital, GrenobleUrinary Tract Infections
Start: 2016-04-30End: 2018-09-30Updated: 2018-06-06
Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections
CompletedNCT02959957
Håkan HanbergerUrinary Tract Infections
Start: 2016-05-20End: 2019-08-31Updated: 2019-09-16

Unknown Phase

Plasma Protein Binding and PK/PD of Total and Unbound Temocillin Non-ICU Patients
NCT03557840
Paul M. TulkensAntibacterial Agents, Drug Monitoring, Infection +3
Start: 2019-04-01End: 2023-04-01Target: 60Updated: 2022-05-31
Temocillin in ESBL-Enterobacteriaceae Infections
CompletedNCT05413772
Assistance Publique - Hôpitaux de ParisInfectious Disease
Start: 2022-10-20End: 2022-11-24Updated: 2023-02-06

Related Papers

Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant <i>Enterobacterales</i> (ASTARTÉ): protocol for a randomised, pragmatic trial
BMJ Open2021-09-0112 citations